Ixazomib
Ixazomib (Ninlaro, Takeda Pharma A/S) has 1 EU-approved indication in 1 tumour type.
| Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|
| Multiple myeloma1 | |||
None | + lenalidomide and dexamethasone | 2L | After at least one prior therapy |
Full text of section 4.1 (therapeutic indications)
NINLARO in combination with lenalidomide and dexamethasone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
Label history
26 changes to the Ninlaro label since 2017, none of them to the indications. Newest first, in the words of EMA's record of each procedure.
Changes